Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Gains Budget Increase In FY 2017… And Not Through Fees

Executive Summary

Omnibus legislation to fund the federal government for FY 2017 includes an increase in non-user fee funds, which should please stakeholders.

You may also be interested in...



FDA Safety Initiatives Could Suffer Under Trump's Budget Proposal

User fee-heavy budget proposes appears to tie into Trump's broader deregulatory strategy; CDER and CBER would have to make cuts to non-user fee safety initiatives.

Breakthrough-Style Program For ANDAs Added To House User Fee Bill

Energy and Commerce subcommittee unanimously advances reauthorization legislation with four added amendments, including one that would allow for certain generic sponsors to meet early and often with FDA to speed development.

Breakthrough-Style Program For ANDAs Added To House User Fee Bill

Energy and Commerce subcommittee unanimously advances reauthorization legislation with four added amendments, including one that would allow for certain generic sponsors to meet early and often with FDA to speed development.

Related Content

Topics

UsernamePublicRestriction

Register

PS120537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel